Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
van Opijnen MP, Broekman MLD, Cuppen E, Dubbink HJ, Ter Elst A, van Eijk R, Mühlebner A, Jansen C, van der Geize R, Speel EM, Groenen PJTA, de Vos FYF, Wesseling P, de Leng WWJ, Maas SLN. van Opijnen MP, et al. Among authors: dubbink hj. J Neurooncol. 2024 Feb;166(3):485-492. doi: 10.1007/s11060-024-04568-8. Epub 2024 Jan 29. J Neurooncol. 2024. PMID: 38285243 Free PMC article. Review.
Federated learning enables big data for rare cancer boundary detection.
Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, Foley P, Gruzdev A, Karkada D, Davatzikos C, Sako C, Ghodasara S, Bilello M, Mohan S, Vollmuth P, Brugnara G, Preetha CJ, Sahm F, Maier-Hein K, Zenk M, Bendszus M, Wick W, Calabrese E, Rudie J, Villanueva-Meyer J, Cha S, Ingalhalikar M, Jadhav M, Pandey U, Saini J, Garrett J, Larson M, Jeraj R, Currie S, Frood R, Fatania K, Huang RY, Chang K, Balaña C, Capellades J, Puig J, Trenkler J, Pichler J, Necker G, Haunschmidt A, Meckel S, Shukla G, Liem S, Alexander GS, Lombardo J, Palmer JD, Flanders AE, Dicker AP, Sair HI, Jones CK, Venkataraman A, Jiang M, So TY, Chen C, Heng PA, Dou Q, Kozubek M, Lux F, Michálek J, Matula P, Keřkovský M, Kopřivová T, Dostál M, Vybíhal V, Vogelbaum MA, Mitchell JR, Farinhas J, Maldjian JA, Yogananda CGB, Pinho MC, Reddy D, Holcomb J, Wagner BC, Ellingson BM, Cloughesy TF, Raymond C, Oughourlian T, Hagiwara A, Wang C, To MS, Bhardwaj S, Chong C, Agzarian M, Falcão AX, Martins SB, Teixeira BCA, Sprenger F, Menotti D, Lucio DR, LaMontagne P, Marcus D, Wiestler B, Kofler F, Ezhov I, Metz M, Jain R, Lee M, Lui YW, McKinley R, Slotboom J, Radojewski P, Meier R, Wiest R, Murcia D, Fu E, Haas R, Thompson… See abstract for full author list ➔ Pati S, et al. Among authors: dubbink hj. Nat Commun. 2022 Dec 5;13(1):7346. doi: 10.1038/s41467-022-33407-5. Nat Commun. 2022. PMID: 36470898 Free PMC article.
Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation.
Wijnenga MMJ, Maas SLN, van Dis V, Tesileanu CMS, Kros JM, Dirven L, Hazelbag HM, Dubbink HJ, Vincent AJPE, French PJ, van den Bent MJ. Wijnenga MMJ, et al. Among authors: dubbink hj. Neurooncol Adv. 2023 Jun 21;5(1):vdad075. doi: 10.1093/noajnl/vdad075. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37441086 Free PMC article. No abstract available.
External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium.
van der Leest P, Rozendal P, Hinrichs J, van Noesel CJM, Zwaenepoel K, Deiman B, Huijsmans CJJ, van Eijk R, Speel EJM, van Haastert RJ, Ligtenberg MJL, van Schaik RHN, Jansen MPHM, Dubbink HJ, de Leng WW, Leers MPG, Tamminga M, van den Broek D, van Kempen LC, Schuuring E. van der Leest P, et al. Among authors: dubbink hj. Clin Chem. 2024 May 2;70(5):759-767. doi: 10.1093/clinchem/hvae014. Clin Chem. 2024. PMID: 38484302
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD, Plomp P, Paats MS, van Helvert S, Elst AT, van den Berg A, Dubbink HJ, van Geffen WH, Zhang L, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering-Kappelle LBM, Jalving M, Kluiver J, Koopman B, van Kruchten M, van der Logt EMJ, Piet B, van Putten J, Reitsma BH, Rutgers SR, de Vries M, Stigt JA, Groves MR, Timens W, Willems SM, van Kempen LC, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: dubbink hj. ESMO Open. 2024 Nov;9(11):103966. doi: 10.1016/j.esmoop.2024.103966. Epub 2024 Nov 4. ESMO Open. 2024. PMID: 39500140 Free PMC article.
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.
Ernst SM, Uzun S, Paats MS, van Marion R, Atmodimedjo PN, de Jonge E, van Schaik RHN, Aerts JGJV, von der Thüsen JH, Dubbink HJ, Dingemans AC. Ernst SM, et al. Among authors: dubbink hj. JCO Precis Oncol. 2023 Sep;7:e2300451. doi: 10.1200/PO.23.00451. JCO Precis Oncol. 2023. PMID: 38096473 Free PMC article.
138 results